Details

Autor(en) / Beteiligte

• Feitsma, Eline A.
• Janssen, Yester F.
• Boersma, Hendrikus H.
• van Sleen, Yannick
• van Baarle, Debbie
• Alleva, David G.
• Lancaster, Thomas M.
• Sathiyaseelan, Thillainaygam
• Murikipudi, Sylaja
• Delpero, Andrea R.
• Scully, Melanie M.
• Ragupathy, Ramya
• Kotha, Sravya
• Haworth, Jeffrey R.
• Shah, Nishit J.
• Rao, Vidhya
• Nagre, Shashikant
• Ronca, Shannon E.
• Green, Freedom M.
• Aminetzah, Ari
• Sollie, Frans
• Kruijff, Schelto
• Brom, Maarten
• van Dam, Gooitzen M.
• Zion, Todd C.

Titel

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

Ist Teil von

• Vaccine, 2023-03, Vol.41 (13), p.2184-2197

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

ScienceDirect

Beschreibungen/Notizen

• Previous interim data from a phase I study of AKS-452, a subunit vaccine comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor binding domain (SP/RBD) emulsified in the water-in-oil adjuvant, Montanide™ ISA 720, suggested a good safety and immunogenicity profile in healthy adults. This phase I study was completed and two dosing regimens were further evaluated in this phase II study. This phase II randomized, open-labelled, parallel group study was conducted at a single site in The Netherlands with 52 healthy adults (18 – 72 years) receiving AKS-452 subcutaneously at one 90 µg dose (cohort 1, 26 subjects) or two 45 µg doses 28 days apart (cohort 2, 26 subjects). Serum samples were collected at the first dose (day 0) and at days 28, 56, 90, and 180. Safety and immunogenicity endpoints were assessed, along with induction of IgG isotypes, cross-reactive immunity against viral variants, and IFN-γ T cell responses. All AEs were mild/moderate (grades 1 or 2), and no SAEs were attributable to AKS-452. Seroconversion rates reached 100% in both cohorts, although cohort 2 showed greater geometric mean IgG titers that were stable through day 180 and associated with enhanced potencies of SP/RBD-ACE2 binding inhibition and live virus neutralization. AKS-452-induced IgG titers strongly bound mutant SP/RBD from several SARS-CoV-2 variants (including Omicrons) that were predominantly of the favorable IgG1/3 isotype and IFN-γ-producing T cell phenotype. These favorable safety and immunogenicity profiles of the candidate vaccine as demonstrated in this phase II study are consistent with those of the phase I study (ClinicalTrials.gov: NCT04681092) and suggest that a total of 90 µg received in 2 doses may offer a greater duration of cross-reactive neutralizing titers than when given in a single dose.